Sarah Jenkins – Asylia Therapeutics (“Asylia”), a development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases, today announced the

Proceeds will support development of novel antibody drugs that convert immunologically “cold” tumors into treatable “hot” tumors, with the goal of enhancing effectiveness of cancer

Houston, Texas. February 8, 2021 – Houston: the true third coast of innovation. Texas is home to more than 5,400 life science R&D and manufacturing

Houston, Texas. June 6, 2020 – Asylia Therapeutics (“Asylia”), a Texas-based, privately held, development-stage biopharmaceutical company developing novel immune modulating therapies for cancer, autoimmune, and

Houston, Texas.  May 11, 2020 – Asylia Therapeutics (“Asylia”), a Texas-based, privately held, development-stage biopharmaceutical company developing novel immune modulating therapies for cancer, autoimmune, and

The attached article demonstrates a key role for tumor-derived HSP70 in the development of robust anti-tumor immune responses. The results validate HSP70 as a target